Pharma Stocks Outlook For The Week - 23 to 27.10.2017
Pharma Stocks Outlook For The Week - 23 to 27.10.2017
( www.rupeedesk.in )
The stocks of pharmaceutical companies are likely to consolidate next week, as investors look forward to companies earnings for the September quarter and commentary by their management. Having faced multiple challenges during past few quarters, the trend seems to be turning for Indian pharma. We expects companies to report better growth in Jul-Sep compared to Apr- Jun, as re-stocking by distribution channels after the rollout of the goods and services tax is seen boosting domestic revenue. Companies had reported dismal numbers for Apr-Jun, as distribution channels liquidated existing stock without refreshing it due to the implementation of the new indirect tax regime on Jul 1. While expect revenues of companies to be boosted by faster approval for generic drugs by the US Food and Drug Administration, others fear more pricing pressure due to greater competition. On the regulatory front, the focus is on Sun Pharmaceutical Industries, which is awaiting re-inspection of its Halol facility by the US FDA. At Sun Pharma's annual general meeting last month, Managing Director Dilip Shanghvi had said that the company had completed remedial process at the facility, which received a warning letter from the regulator in December 2015.
Source : Cogencis Information Services Ltd.
Click Below Link
( www.rupeedesk.in )
The stocks of pharmaceutical companies are likely to consolidate next week, as investors look forward to companies earnings for the September quarter and commentary by their management. Having faced multiple challenges during past few quarters, the trend seems to be turning for Indian pharma. We expects companies to report better growth in Jul-Sep compared to Apr- Jun, as re-stocking by distribution channels after the rollout of the goods and services tax is seen boosting domestic revenue. Companies had reported dismal numbers for Apr-Jun, as distribution channels liquidated existing stock without refreshing it due to the implementation of the new indirect tax regime on Jul 1. While expect revenues of companies to be boosted by faster approval for generic drugs by the US Food and Drug Administration, others fear more pricing pressure due to greater competition. On the regulatory front, the focus is on Sun Pharmaceutical Industries, which is awaiting re-inspection of its Halol facility by the US FDA. At Sun Pharma's annual general meeting last month, Managing Director Dilip Shanghvi had said that the company had completed remedial process at the facility, which received a warning letter from the regulator in December 2015.
Cadila Healthcare - Down
Auropharma - Down
Sunpharma - Up
Auropharma - Down
Sunpharma - Up
Lupin - Down
Cipla - Down
Cipla - Down
Free Intraday Tips : Join Our Whatsapp No : 9841986753
Free Commodity Tips : Join our Whatsapp No : 9094047040
Source : Cogencis Information Services Ltd.
